ArticleInternational journal of cancer2022
Mendelian randomization analyses of 23 known and suspected risk factors and biomarkers for breast cancer overall and by molecular subtypes.
Article in International journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Sleep Traits to the Risk of Breast Cancer Disease Incidence, Adverse Progression and Mortality: Evidence From a Global Systematic Review and Meta-Analysis.International journal of public health · 2025Pooled it
- Alcohol consumption and its association with cancer, cardiovascular, liver and brain diseases: a systematic review of Mendelian randomization studies.Frontiers in epidemiology · 2024Pooled it
- Morning chronotype and digestive tract cancers: Mendelian randomization study.International journal of cancer · 2023Pooled it
- Identifying druggable proteins of the association of chronotype on breast cancer using Mendelian randomization.Communications medicine · 2026Article
- BMI-Dependent Correlations of Sex Hormone Genes with Simple Endometrial Hyperplasia.Life (Basel, Switzerland) · 2026Article
- Deciphering the causal nexus of mitochondrial biology with breast cancer.Discover oncology · 2026Article
- Genetic Evidence Links Gestational Diabetes Mellitus to Increased ER-Negative Breast Cancer Risk Through a Mendelian Randomization Analysis.International journal of endocrinology · 2026Article
- Impact of breast reconstruction on quality of life among women after mastectomy.Journal of Taibah University Medical Sciences · 2025Article
- Independent effects of mental health disorders on breast cancer and their mediating factors: evidence from NHANES and two-step Mendelian randomization.Discover oncology · 2025Article
- Causal Effects of Breast Cancer Risk Factors across Hormone Receptor Breast Cancer Subtypes: A Two-Sample Mendelian Randomization Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- A narrative review of sleep and breast cancer: from epidemiology to mechanisms.Cancer causes & control : CCC · 2025Review
- Global, regional, and national time trends in mortality for breast cancer, 1992-2021: an age-period-cohort analysis for the global burden of disease 2021 study.BMC public health · 2025Article
- Association between the red blood cell distribution width-to-albumin ratio and risk of colorectal and gastric cancers: a cross-sectional study using NHANES 2005-2018.BMC gastroenterology · 2025Article
- Biomarker identification for Alzheimer's disease through integration of comprehensive Mendelian randomization and proteomics data.Journal of translational medicine · 2025Article
- Multilayer analysis of ethnically diverse blood and urine biomarkers for breast cancer risk and prognosis.Scientific reports · 2025Article
- Relationship between diagnostic characteristics, lifestyle habits and breast cancer subtypes in women.Revista latino-americana de enfermagem · 2025Article
- Causal relationship between physical activity and common gynecologic conditions: a two-sample Mendelian randomization study.American journal of translational research · 2025Article
- Diet quality indices are associated with breast cancer by molecular subtypes in Mexican women.European journal of nutrition · 2024Article
- Causality between autoimmune diseases and breast cancer: a two-sample Mendelian randomization study in a European population.Discover oncology · 2024Article
- Mammographic density mediates the protective effect of early-life body size on breast cancer risk.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Many risk factors have been identified for breast cancer. The potential causality for some of them remains uncertain, and few studies have comprehensively investigated these associations by molecular subtypes. We performed a two-sample Mendelian randomization (MR) study to evaluate potential causal associations of 23 known and suspected risk factors and biomarkers with breast cancer risk overall and by molecular subtypes using data from the Breast Cancer Association Consortium. The inverse-variance weighted method was used to estimate odds ratios (OR) and 95% confidence interval (CI) for association of each trait with breast cancer risk. Significant associations with breast cancer risk were found for 15 traits, including age at menarche, age at menopause, body mass index, waist-to-hip ratio, height, physical activity, cigarette smoking, sleep duration, and morning-preference chronotype, and six blood biomarkers (estrogens, insulin-like growth factor-1, sex hormone-binding globulin [SHBG], telomere length, HDL-cholesterol and fasting insulin). Noticeably, an increased circulating SHBG was associated with a reduced risk of estrogen receptor (ER)-positive cancer (OR = 0.83, 95% CI: 0.73-0.94), but an elevated risk of ER-negative (OR = 1.12, 95% CI: 0.93-1.36) and triple negative cancer (OR = 1.19, 95% CI: 0.92-1.54) (P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.